Removes extraneous word "maker" in first bullet
** J.P. Morgan raises PT on drugmaker Pacira Biosciences PCRX.O to $21 from $11
** New PT represents a 20.6% downside to the stocks's last close
** Says it maintains its "underweight" rating, increasing its PT "primarily reflecting later generic entry"
** Brokerage says co's current share price of ~$26 implies that the market is assuming generic entry for co's pain management drug, Exparel in 2035+, which it considers a "highly optimistic scenario" for PCRX and underestimates "competitive risk"
** Says "assume a more balanced outcome with market entry late this decade"
** Co's lead drug Exparel is a pain-management drug used after surgery
** Stock has fallen 11.4% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。